Document Detail


Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts.
MedLine Citation:
PMID:  7570985     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have examined the effects of rapamycin (RPM) on transplant vasculopathy in long-surviving F344 rat heart allografts transplanted heterotopically into Lewis recipients. RPM was administered intraperitoneally for the first 14 days in groups 1 and 2 (0.5 and 2 mg/kg/day), and daily throughout the follow-up period in groups 3 (0.5 mg/kg/day) and 4 (5 mg/kg for 14 days, followed by a maintenance dose of 2.5 mg/kg/day). Treatment with low dose cyclosporine (CsA; 1.5 mg/kg/day) in combination with RPM (0.5 mg/kg/day for 14 days) (group 5) and immunosuppression with CsA only (5 mg/kg for 14 days, followed by 1.5 mg/kg/day) (group 6) were also examined. F344 isograft recipients treated with RPM (0.5 mg/kg/day for 14 days) (group 7), those that were untreated (group 8), and hearts in naive F344 animals (group 9) served as controls. Grafts of group 1 were removed at 50, 75, 100, 150, and 200 days and infiltrating cell populations and surface molecules were compared with those of the other groups at 100 days. All allografts in treated hosts functioned > 100 days; in contrast, grafts in untreated recipients were rejected acutely by 8 +/- 1 days (MST +/- SD). The incidence of transplant vasculopathy in group 1 increased progressively (MST +/- SD = 10 +/- 2%, 59 +/- 7%, 85 +/- 15%, and 80 +/- 12% at 50, 100, 150, and 200 days, respectively), as manifested by myointimal proliferation with dense mononuclear infiltration (predominantly ED1+ macrophages). Numbers of MHC class II+ infiltrating cells were prominent, as was expression of adhesion molecules and cytokines. The incidence of graft disease and extent of cellular infiltration at 100 days was significantly lower in animals receiving increased maintenance doses of RPM (for groups 2, 3, and 4: 25 +/- 15%, 22 +/- 11%, and 10 +/- 3%, respectively; P < 0.005). CsA treatment either in combination with RPM or alone (groups 5 and 6) failed to improve transplant vasculopathy, but reduced mononuclear cell infiltration. Isografts (groups 7 and 8) and naive hearts (group 9) developed no structural abnormalities throughout the follow-up period, regardless of RPM treatment. We conclude that the extent of transplant vasculopathy can be reduced markedly in this rat cardiac transplant model with maintenance RPM. Addition of CsA modifies the morphological picture but does not improve myointimal proliferation.
Authors:
C Schmid; U Heemann; H Azuma; N L Tilney
Related Documents :
11468555 - Combined fty720/cyclosporine treatment promotes graft survival and lowers the periphera...
2785025 - The effect of cyclosporin a administration and its withdrawal on bone mineral metabolis...
3284095 - Cyclosporine pharmacokinetics in pancreas transplant recipients.
18089405 - Anti-cd25 mab, anti-il2 mab, and il2 block tolerance induction through anti-cd154 mab a...
8860605 - The effects of subconjunctival verapamil on filtering blebs in rabbits.
1166765 - Some effects of methyl mercury salts on the rabbit nervous system.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Transplantation     Volume:  60     ISSN:  0041-1337     ISO Abbreviation:  Transplantation     Publication Date:  1995 Oct 
Date Detail:
Created Date:  1995-11-22     Completed Date:  1995-11-22     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  729-33     Citation Subset:  IM    
Affiliation:
Surgical Research Laboratory, Harvard Medical School, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Division / drug effects
Cyclosporine / therapeutic use
Dose-Response Relationship, Drug
Heart Transplantation / adverse effects*
Immunohistochemistry
Immunosuppressive Agents / therapeutic use*
Male
Polyenes / therapeutic use*
Rats
Rats, Inbred F344
Rats, Inbred Lew
Sirolimus
Time Factors
Tunica Intima / cytology,  drug effects
Vascular Diseases / etiology,  pathology,  prevention & control*
Ventricular Function / drug effects
Grant Support
ID/Acronym/Agency:
9R 01 DK 46190-20/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Polyenes; 53123-88-9/Sirolimus; 59865-13-3/Cyclosporine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coronary atherosclerosis in transplanted mouse hearts. IV Effects of treatment with monoclonal antib...
Next Document:  Human vascular endothelial cells do not induce anergy in allogeneic CD4+ T cells unless costimulatio...